Shire Wrings Life Out Of Adderall XR Despite Actavis Generic Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Branded Adderall XR will remain competitive, Shire CEO Angus Russell predicts during the company’s second quarter sales and earnings call, despite the launch of the first generic.
You may also be interested in...
Shire Full Of Hopes For Vyvanse Binge-Eating Indication
First Phase II results in expansion program for the ADHD therapy show strong response in the eating disorder, but the company faces a regulatory challenge in gaining the first approval for the condition.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.